Boehringer Ingelheim has received FDA approval for its drug Ofev as a first-line treatment for non-small cell lung cancer. The approval offers a new option for patients with metastatic NSCLC, combining Ofev with chemotherapy for better outcomes.
.png)
Lupin Limited has announced FDA approval for its Brivaracetam Oral Solution 10 mg/mL, a bioequivalent of UCB’s Briviact, designed to treat partial-onset seizures in patients 1 month and older. The launch is now underway in the U.S.
.jpeg)
Gleneagles Hospital, Mumbai, partners with Medtronic India to launch a Renal Denervation Therapy Centre, offering advanced treatment for resistant hypertension and improving outcomes.
Bayer's Nubeqa receives expanded approval in India for metastatic hormone-sensitive prostate cancer, offering a non-chemotherapy treatment with ADT for advanced cases.
Lilly and Company has announced that its Retevmo (selpercatinib) has met its primary endpoint in the LIBRETTO-432 Phase 3 trial, showing a significant improvement in event-free survival for early-stage RET fusion-positive NSCLC patients.
Novartis announces sale of 70.68% stake in Novartis India for Rs 1,446 crore, with an offer to buy an additional 26% from public shareholders, marking a major strategic shift.
GSK plc has reported strong real-world results for its RSV vaccine, showing major reductions in RSV-related hospitalizations and serious complications in adults aged 60 and older at RSVVW’26 in Rome.
Teva and Sanofi reveal duvakitug’s 44-week success, showing lasting remission in ulcerative colitis and Crohn’s patients, reinforcing TL1A as a promising treatment target.
Eli Lilly’s Retevmo delivers significant gains in event-free survival for early-stage RET fusion-positive NSCLC, marking a breakthrough in targeted lung cancer therapy.
Bharat Biotech is exploring a new biologics manufacturing facility near Chennai, aiming to produce advanced therapies including monoclonal antibodies and diabetes treatments as part of its long-term growth strategy.
.jpg)
.jpg)
, CDSCO.jpg)